



## PRESS RELEASE

### Half year report on Adocia's liquidity agreement with Kepler Capital Markets

**Lyon, France, January 8, 2016** – Under the liquidity agreement entrusted by Adocia to Kepler Capital Markets, the following resources were listed on the liquidity account as at December 31, 2015 :

- 4,185 shares of Adocia and
- 132,740.22 euros in cash.

At the last half year report dated June 30, 2015, the following resources were listed on the liquidity account:

- 2,257 shares of Adocia and
- 83,378.96 euros in cash.

#### About Adocia:

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia's insulin formulation portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia's clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a fast-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a fast-acting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500).

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro programs.

Adocia's extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaborations programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn® nanotechnology platform.

*Adocia aims to deliver "Innovative medicine for everyone, everywhere."*

To learn more about Adocia, please visit us at [www.adocia.com](http://www.adocia.com)



ENTERNEXT | TECH40 | LABEL | 2015



**ADOC**  
**LISTED**  
**EURONEXT**

**For more information please contact:**

<p><b>Adocia</b> Gérard Soula Chairman and CEO of Adocia <a href="mailto:contactinvestisseurs@adocia.com">contactinvestisseurs@adocia.com</a> Tel.: +33 4 72 610 610</p>	<p><b>Adocia Press Relations</b> <b>ALIZE RP</b> Caroline Carmagnol <a href="mailto:caroline@alizerp.com">caroline@alizerp.com</a> <a href="mailto:adocia@alizerp.com">adocia@alizerp.com</a> Tel.: + 33 1 44 54 36 61</p>
--	--